Araris will use its linker technology to generate multi-warhead ADCs for “undisclosed targets” provided by Chugai.

Trop2是在多种实体瘤中广泛表达的蛋白，其中包括HR阳性，HER2低表达或阴性乳腺癌。阿斯利康和第一三共在2020年7月达成协议，合作开发这款ADC。目前，Datroway治疗乳腺癌的上市申请在美国、欧盟和中国等其它国家和地区正在接受审评。

Daiichi Sankyo Co. Ltd.’s trophoblast cell surface antigen 2 (Trop2)-directed antibody-drug conjugate (ADC), datopotamab ...

Roche has once again returned to China to bolster its antibody-drug conjugate pipeline, this time striking a licensing deal ...

Alphamab Oncology (stock code: 9966.HK) announced that anti-HER2 bispecific antibody-drug conjugate (ADC) JSKN003 has received approval from the Center for Drug Evaluation (CDE) of the National ...

This is the first domestically developed TROP2 ADC approved for marketing in China and the first domestically developed ADC fully approved for marketing in China. The approval is based on the positive ...

LAS VEGAS, NV, UNITED STATES, December 10, 2024 /EINPresswire / -- The ADC market is projected to experience rapid growth due to the expansion of indications for already approved therapies ...

This is the first domestically developed TROP2 ADC approved for marketing in China and the first domestically developed ADC fully approved for marketing in China. The approval is based on the ...

a high-concentration subcutaneous co-formulation consisting of anti-HER2 bispecific antibody-drug conjugate (ADC) and PD-L1 immune checkpoint inhibitor, has been approved by the Center for Drug ...

26, 2024 /PRNewswire/ -- Alphamab Oncology (stock code: 9966.HK) announced that a phase I/II clinical trial (Study ID: JSKN033-102) of JSKN033, a high-concentration subcutaneous co-formulation ...